Nuraveris

Nuraveris is a biotechnology company focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory diseases. The company's core research centers on inhibiting SARM1 (Sterile Alpha and TIR motif-containing protein 1), a protein identified as a central driver of axonal degeneration. By targeting this pathway, Nuraveris seeks to provide neuroprotective treatments for conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, and various forms of neuropathy. The company is led by a team of experienced neuroscience drug hunters and is currently in the pre-clinical stage of development.